Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 5/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025286 | 1.00 | SLC15A1 (0.51) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL6243841 | 1.00 | SLC15A1 (0.51) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL8690443 | 0.81 | EPHX1 (0.48) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL11412673 | 0.81 | EPHX1 (0.48) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL9675556 | 0.79 | CSNK1E (0.53) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL6730587 | 0.78 | SLC6A4 (0.54) | ANPEPTAAR1SLC6A4CYP1A2 | |
| SCHEMBL9740410 | 0.77 | EPHX1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL7190709 | 0.77 | EPHX1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL6446370 | 0.77 | EPHX1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL22431194 | 0.77 | EPHX1 (0.58) | SLC15A1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751145-B1 | HIV-protease inhibitors | JAPAN ENERGY CORP (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-6673772-B2 | INHIBITING THE ENZYMATIC ACTIVITY OF HIV PROTEASE | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| US-6440946-B1 | ANTI-HIV ACTIVITY IMPROVED IN ABSORPTION WHEN ORALLY ADMINISTERED, STABILITY, PHYSICOCHEMICAL PROPERTIES, REDUCED SIDE EFFECTS; HIV REVERSE TRANSCRIPTASE INHIBITOR, HIV PROTEASE INHIBITOR OR CCR5 ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-27 | — | — | US | disclosed |
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| EP-1157997-A1 | NOVEL DIPEPTIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN ENERGY CORPORATION (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6222043-B1 | COUPLING 2-AMIDO-THIAZOLE DERIVATIVE WITH 2-PHENYL4-(PROTECTED)AMINO-BUTYRIC ACID; DEPROTECTING AMINO PROTECTING GROUP; ACYLATING PRODUCT WITH CARBOXYLIC ACID CONTAINING CARBOCYCLIC OR HETEROCYCLIC GROUP; DEPROTECTING | JAPAN ENERGY CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| US-5962640-A | MAKING A DIPEPTIDE COMPOUND OF GIVEN FORMULA COMPRISING A ALPHA-AMINOCARBOXAMIDE INCLUDING CYCLIC GROUP LINKED TO 3-AMINO-2-HYDROXY-4-PHENYLBUTANOYL RESIDUE; HIV PROTEASE INHIBITION AND EXCELLENT BIOAVAILABILITY FROM DIGESTIVE TRACT | JAPAN ENERGY CORPORATION (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5932550-A | PROTEASE INHIBITOR; AIDS THERAPY | JAPAN ENERGY CORPORATION (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0751145-A2 | HIV-protease inhibitors | Japan Energy Corporation (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DNPEP, PEPD, ANPEP | SLC15A1 659/4885ALPI 2762/4885PKM 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.